Investigating the Immunogenicity of PA63 Antigen in Free form and Loaded in PLGA Nanoparticle in Mice

Abstract

Background: So far, an ideal vaccine for anthrax has not been approved. PA63 antigen has antigenic properties, and scientists use this antigen to produce new generations of vaccines. The main aim of this research is to investigate the ability to produce antibodies and immunogenicity of PA63 recombinant antigen-loaded in PLGA nanoparticles in mice as a potential vaccine candidate.